



Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City

June 14, 2013

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations, today announced CEO Mark L. Baum will present at the National Investment Banking Association (NIBA) conference, set for June 17-19 in New York City. The Imprimis presentation is scheduled for June 18th.

About Imprimis Pharmaceuticals, Inc. Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through its exclusive strategic relationship with Professional Compounding Centers of America (PCCA), the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technologies, as well as proprietary drug formulations for new indications and market data obtained through PCCA, to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need utilizing the FDA 505(b)(2) regulatory pathway. Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes the Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit <http://imprimispharma.com/>.

About NIBA The National Investment Banking Association (NIBA) is the only not-for-profit association for national, regional and independent broker dealers, investment banking firms, investment advisors, and related capital market service providers. Its member firms: are responsible for 90 percent of all IPO's under \$20 million; have successfully completed more than 1,000 equity offerings; have raised over \$10 billion in new capital for emerging growth companies; represent more than 8,800 registered representatives; have more than \$76 billion in assets under management; and represent more than 60 key industry services. For more information, visit <http://nibanet.org/>.

Contact: Josh Berg
Imprimis Pharmaceuticals, Inc.
(858) 704 4041

SOURCE Imprimis Pharmaceuticals, Inc.